Merck & Company, Inc.s in-depth stock price analysis indicates that the stock price has rallied 3.69% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 2.07% . Looking at the past 52 week period, the stock price is up at 30.84% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of Merck & Company, Inc. has a positive value of 11.26 compared to overall market. Merck & Company, Inc. (NYSE:MRK) has tumbled 0.22% during the past week, however, the bigger picture is still very bullish; the stocks have advanced and posted positive gains of 2.9% in the last four weeks. The stocks have underperformed the S&P 500 by 1.02% during the past week but Merck & Company, Inc. (NYSE:MRK) it has outperformed the index in 4 weeks by 1.06%.
Merck & Company, Inc. (NYSE:MRK) stock ended Friday session in the red zone in a volatile trading. The stock closed down 0.24 points or 0.37% at $64.15 with 8,531,370 shares getting traded. Post opening the session at $64.32, the shares hit an intraday low of $63.96 and an intraday high of $64.57 and the price was in this range throughout the day. The company has a market cap of $176,870 million and the number of outstanding shares has been calculated to be 2,757,137,500 shares. The 52-week high of Merck & Company, Inc. (NYSE:MRK) is $65.46 and the 52-week low is $48.28.
Merck & Co. Last issued its quarterly earnings results on Feb 2, 2017. The company reported $0.89 EPS for the quarter. Analyst had a consensus estimate of $0.89. The company had revenue of $10115.00 million for the quarter, compared to analysts expectations of $10233.89 million. The companys revenue was down -1.0 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.93 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Merck & Co. was Initiated by Bryan Garnier to Buy on Jan 13, 2017. Merck & Co. was Upgraded by Piper Jaffray to Overweight on Jan 12, 2017. Merck & Co. was Upgraded by Morgan Stanley to Overweight on Jan 12, 2017. Merck & Co. was Upgraded by Guggenheim to Buy on Jan 12, 2017. Merck & Co. was Downgraded by Jefferies to Underperform on Dec 19, 2016.
Company has reported several Insider transactions to the SEC, on Feb 6, 2017, Michael J Holston (EVP, General Counsel) sold 91,959 shares at 63.85 per share price.On Feb 6, 2017, Peter C Wendell (director) sold 15,000 shares at 63.69 per share price.On Feb 6, 2017, Adam H Schechter (EVP & Pres-Global Human Health) sold 36,335 shares at 63.73 per share price.
Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service.